{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:24:32Z","timestamp":1770139472161,"version":"3.49.0"},"reference-count":102,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T00:00:00Z","timestamp":1572739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>The prevalence of obesity among persons living with human immunodeficiency virus (HIV) has increased significantly and may be linked to the use of antiretroviral therapy. Although weight\u2010loss medications approved by the U.S. Food and Drug Administration are recommended as an adjunct to diet and exercise to treat obesity in the general population, little is known about the safety and efficacy of these drugs specifically in persons living with HIV. We review the available evidence regarding the effective use of weight\u2010loss pharmacotherapy in persons living with HIV and its potential to interact with antiretroviral therapy. Persons living with HIV are frequently not reported or included in clinical trials for weight\u2010loss medications; however, treatment efficacy is likely similar to the general population. Several important reported or theoretical drug\u2010drug interactions exist between antiobesity pharmacotherapy and antiretroviral therapy. Orlistat is a weight\u2010loss drug available in the United States without a prescription and was linked to HIV viral rebound in several case reports. Clinicians should be aware of the potential for loss of HIV viremia control when certain weight\u2010loss pharmacotherapies are used in combination with antiretrovirals.<\/jats:p>","DOI":"10.1002\/phar.2342","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T23:09:26Z","timestamp":1570748966000},"page":"1204-1215","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety and Efficacy of Weight\u2010Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug\u2010Drug Interactions with Antiretroviral Therapy"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9962-0995","authenticated-orcid":false,"given":"Rebecca J.","family":"Cope","sequence":"first","affiliation":[{"name":"LIU Pharmacy Brooklyn New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Briann S.","family":"Fischetti","sequence":"additional","affiliation":[{"name":"LIU Pharmacy Brooklyn New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca K.","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"Touro College of Pharmacy New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trisha M.","family":"Lepa","sequence":"additional","affiliation":[{"name":"The Brooklyn Hospital Brooklyn New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Sorbera","sequence":"additional","affiliation":[{"name":"LIU Pharmacy Brooklyn New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,11,3]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ192"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.38"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jana.2009.02.006"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0147"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000010"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jada.2004.07.031"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2348"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3415"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"e_1_2_4_12_1","volume-title":"Xenical [package insert]","year":"2012"},{"key":"e_1_2_4_13_1","volume-title":"Belviq [package insert]","year":"2017"},{"key":"e_1_2_4_14_1","volume-title":"Saxenda (liraglutide) [prescribing information]","year":"2018"},{"key":"e_1_2_4_15_1","volume-title":"Contrave [package insert]","year":"2018"},{"key":"e_1_2_4_16_1","volume-title":"Qsymia [package insert]","year":"2017"},{"key":"e_1_2_4_17_1","volume-title":"Alli [package insert]","year":"2007"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127000204200908"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04232.x"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831010-00005"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9290-9"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.155"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.8.1288"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11509-4"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.235"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801128"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2000.8"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2000.00720.x"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.9.2.160"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2002.tb11307.x"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.6.1033"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.7.1123"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200211000-00026"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2002.00237.x"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802281"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01474.x"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00467.x"},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.81938"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0017"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22240"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw033"},{"key":"e_1_2_4_43_1","unstructured":"Viiv Healthcare and GlaxoSmithKline group of companies.Summary of biopharmaceutic studies and associated analytical methods (Dolutegravir).2012. Available fromhttp:\/\/www.pmda.go.jp\/drugs\/2014\/P201400046\/340278000_22600AMX00561_K100_1.pdf. Accessed December 1 2018."},{"key":"e_1_2_4_44_1","unstructured":"Gilead Sciences.Elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide fixed\u2010dose combination: summary of biopharmaceutical studies and associated analytical methods. Available fromhttp:\/\/www.pmda.go.jp\/drugs\/2016\/P20160621001\/530614000_22800AMX00409_K100_1.pdf. Accessed December 1 2018."},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.4172\/jbb.1000121"},{"key":"e_1_2_4_46_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.781153"},{"key":"e_1_2_4_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.454"},{"key":"e_1_2_4_48_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767010-00004"},{"key":"e_1_2_4_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909809"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.66"},{"key":"e_1_2_4_51_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1256"},{"key":"e_1_2_4_52_1","unstructured":"Department of Health and Human Services.Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available fromhttp:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf. Section accessed December 8 2018."},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.043414"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0343-6"},{"key":"e_1_2_4_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23648"},{"key":"e_1_2_4_56_1","doi-asserted-by":"publisher","DOI":"10.2165\/11201060-000000000-00000"},{"key":"e_1_2_4_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.120"},{"key":"e_1_2_4_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60307-8"},{"key":"e_1_2_4_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12736"},{"key":"e_1_2_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61267-7"},{"key":"e_1_2_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02656.x"},{"key":"e_1_2_4_63_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2883"},{"key":"e_1_2_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70214-6"},{"key":"e_1_2_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60976-4"},{"key":"e_1_2_4_66_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00278"},{"key":"e_1_2_4_67_1","unstructured":"Liverpool HIV Pharmacology Group [database on the Internet]. Cheshire UK: The University of Liverpool and eMed\u2010 Fusion;2010. Available fromhttp:\/\/www.hiv-druginteractions.org. Accessed September 1 2019."},{"issue":"5","key":"e_1_2_4_68_1","first-page":"255","article-title":"Naltrexone SR\/Bupropion SR (Contrave): a new approach to weight loss in obese adults","volume":"36","author":"Ornellas T","year":"2011","journal-title":"P T."},{"key":"e_1_2_4_69_1","volume-title":"Wellbutrin [package insert]","year":"2017"},{"key":"e_1_2_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"e_1_2_4_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309"},{"key":"e_1_2_4_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"e_1_2_4_73_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0234"},{"key":"e_1_2_4_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1617"},{"key":"e_1_2_4_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100027"},{"key":"e_1_2_4_76_1","unstructured":"RobertsonS MaldarelliNatarajan V et al.Efavirenz induces CYP450 2B6 activity as measured by bupropion hydroxylation in healthy subjects [abstract 761]. 15th Conference on Retroviruses and Opportunistic Infections Boston MA February 3\u20136 2008."},{"key":"e_1_2_4_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200303070-00025"},{"key":"e_1_2_4_78_1","first-page":"100","article-title":"Ritonavir, efavirenz, nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion","volume":"29","author":"Hesse LM","year":"2001","journal-title":"Drug Met Dis"},{"key":"e_1_2_4_79_1","unstructured":"LavrutT GarraffoR FerrandoS et al.Effect of tipranavir\/ritonavir treatment on the steady\u2010state pharmacokinetics of bupropion in healthy volunteers[abstract P4.3\/03]. 11th European AIDS Conference Madrid Spain October 24\u201327 2007."},{"key":"e_1_2_4_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009359524"},{"key":"e_1_2_4_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286981"},{"key":"e_1_2_4_82_1","volume-title":"Genvoya [package insert]","year":"2019"},{"key":"e_1_2_4_83_1","volume-title":"Stribild [package insert]","year":"2019"},{"key":"e_1_2_4_84_1","volume-title":"Adipex\u2010P (phentermine) [package insert]","year":"2017"},{"key":"e_1_2_4_85_1","volume-title":"Topamax (topiramate) [package insert]","year":"2018"},{"key":"e_1_2_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"e_1_2_4_87_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927"},{"key":"e_1_2_4_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"e_1_2_4_89_1","volume-title":"Truvada [package insert]","year":"2018"},{"key":"e_1_2_4_90_1","volume-title":"Vemlidy [package insert]","year":"2016"},{"key":"e_1_2_4_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-013-0168-6"},{"key":"e_1_2_4_92_1","doi-asserted-by":"publisher","DOI":"10.1089\/met.2009.0092"},{"issue":"4","key":"e_1_2_4_93_1","first-page":"233","article-title":"Outcomes of bariatric surgery in human immunodeficiency virus positive individuals: a single center experience","volume":"71","author":"Alfa\u2010Wali M","year":"2016","journal-title":"Minerva Chir"},{"key":"e_1_2_4_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-017-2996-8"},{"key":"e_1_2_4_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3319-4"},{"key":"e_1_2_4_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12755"},{"key":"e_1_2_4_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky551"},{"key":"e_1_2_4_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1227-0"},{"key":"e_1_2_4_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw017"},{"key":"e_1_2_4_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001525"},{"key":"e_1_2_4_101_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001495"},{"key":"e_1_2_4_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx239"},{"key":"e_1_2_4_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-018-0300-4"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2342","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2342","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:22:09Z","timestamp":1761056529000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,3]]},"references-count":102,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/phar.2342"],"URL":"https:\/\/doi.org\/10.1002\/phar.2342","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,3]]},"assertion":[{"value":"2019-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}